The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cidofovir     [(2S)-1-(4-amino-2-oxo- pyrimidin-1-yl)-3...

Synonyms: Forvade, Vistide, Cidofovirum, HPMPC, CHEMBL152, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cidofovir


High impact information on Cidofovir


Chemical compound and disease context of Cidofovir


Biological context of Cidofovir


Anatomical context of Cidofovir


Associations of Cidofovir with other chemical compounds

  • Resistance to foscarnet and cidofovir is associated with mutations in the viral DNA polymerase [20].
  • Amino acid substitutions located in UL54 conserved region IV (N408D, F412C, and F412V), region V (A987G), and delta-region C (L501I, K513E, P522S, and L545S) conferred various levels of resistance to cidofovir and ganciclovir [21].
  • Mutations within DNA Pol conserved regions II (A719T and S724N), VI (L778M, D780N, and L782I), and I (F891C) were shown to induce cross-resistance to ACV, FOS, and ADV, with two of these mutations (S724N and L778M) also conferring significant reduction in CDV susceptibility [22].
  • Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals [23].
  • At higher cidofovir doses, probenecid appeared to block tubular secretion of cidofovir and reduce its renal clearance to a level approaching glomerular filtration [24].

Gene context of Cidofovir


Analytical, diagnostic and therapeutic context of Cidofovir


  1. Treatment of verruca vulgaris with topical cidofovir. Zabawski, E.J., Sands, B., Goetz, D., Naylor, M., Cockerell, C.J. JAMA (1997) [Pubmed]
  2. Topical cidofovir for severe molluscum contagiosum. Davies, E.G., Thrasher, A., Lacey, K., Harper, J. Lancet (1999) [Pubmed]
  3. Nephrogenic diabetes insipidus in a patient taking cidofovir. Schliefer, K., Rockstroh, J.K., Spengler, U., Sauerbruch, T. Lancet (1997) [Pubmed]
  4. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Lalezari, J.P., Stagg, R.J., Kuppermann, B.D., Holland, G.N., Kramer, F., Ives, D.V., Youle, M., Robinson, M.R., Drew, W.L., Jaffe, H.S. Ann. Intern. Med. (1997) [Pubmed]
  5. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Rahhal, F.M., Arevalo, J.F., Chavez de la Paz, E., Munguia, D., Azen, S.P., Freeman, W.R. Ann. Intern. Med. (1996) [Pubmed]
  6. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. De Clercq, E. Trends Pharmacol. Sci. (2002) [Pubmed]
  7. Cidofovir for cytomegalovirus retinitis. Kravcik, S. Ann. Intern. Med. (1997) [Pubmed]
  8. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. De Clercq, E. Clin. Microbiol. Rev. (2003) [Pubmed]
  9. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. De Clercq, E. Clin. Microbiol. Rev. (2001) [Pubmed]
  10. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Liekens, S., Andrei, G., Vandeputte, M., De Clercq, E., Neyts, J. Cancer Res. (1998) [Pubmed]
  11. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. Medveczky, M.M., Horvath, E., Lund, T., Medveczky, P.G. AIDS (1997) [Pubmed]
  12. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J.D., Takeuchi, K., Sugiyama, Y. Mol. Pharmacol. (2007) [Pubmed]
  13. Tubular cell apoptosis and cidofovir-induced acute renal failure. Ortiz, A., Justo, P., Sanz, A., Melero, R., Caramelo, C., Guerrero, M.F., Strutz, F., Müller, G., Barat, A., Egido, J. Antivir. Ther. (Lond.) (2005) [Pubmed]
  14. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Liekens, S., Neyts, J., De Clercq, E., Verbeken, E., Ribatti, D., Presta, M. Cancer Res. (2001) [Pubmed]
  15. A Three-dimensional Model of Human Organic Anion Transporter 1: AROMATIC AMINO ACIDS REQUIRED FOR SUBSTRATE TRANSPORT. Perry, J.L., Dembla-Rajpal, N., Hall, L.A., Pritchard, J.B. J. Biol. Chem. (2006) [Pubmed]
  16. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Abdulkarim, B., Sabri, S., Zelenika, D., Deutsch, E., Frascogna, V., Klijanienko, J., Vainchenker, W., Joab, I., Bourhis, J. Oncogene (2003) [Pubmed]
  17. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients. Kiehl, M.G., Basara, N. Blood (2001) [Pubmed]
  18. Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches. Castagnola, E., Miano, M., Morreale, G., Cristina, E., Chierici, M., Lanino, E. Blood (2001) [Pubmed]
  19. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Neyts, J., Sadler, R., De Clercq, E., Raab-Traub, N., Pagano, J.S. Cancer Res. (1998) [Pubmed]
  20. Resistance of human cytomegalovirus to antiviral drugs. Erice, A. Clin. Microbiol. Rev. (1999) [Pubmed]
  21. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. Cihlar, T., Fuller, M.D., Cherrington, J.M. J. Virol. (1998) [Pubmed]
  22. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. Bestman-Smith, J., Boivin, G. J. Virol. (2003) [Pubmed]
  23. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Cihlar, T., Lin, D.C., Pritchard, J.B., Fuller, M.D., Mendel, D.B., Sweet, D.H. Mol. Pharmacol. (1999) [Pubmed]
  24. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Cundy, K.C., Petty, B.G., Flaherty, J., Fisher, P.E., Polis, M.A., Wachsman, M., Lietman, P.S., Lalezari, J.P., Hitchcock, M.J., Jaffe, H.S. Antimicrob. Agents Chemother. (1995) [Pubmed]
  25. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Abdulkarim, B., Sabri, S., Deutsch, E., Chagraoui, H., Maggiorella, L., Thierry, J., Eschwege, F., Vainchenker, W., Chouaïb, S., Bourhis, J. Oncogene (2002) [Pubmed]
  26. Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2). Uwai, Y., Ida, H., Tsuji, Y., Katsura, T., Inui, K. Pharm. Res. (2007) [Pubmed]
  27. Cidofovir Administered with Radiation Displays an Antiangiogenic Effect Mediated by E6 Inhibition and Subsequent TP53-Dependent VEGF Repression in HPV18+ Cell Lines. Amine, A., Vozenin-Brotons, M.C., Abdulkarim, B., Violot, D., Aubel, C., Bourhis, J. Radiat. Res. (2006) [Pubmed]
  28. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Corbellino, M., Bestetti, G., Scalamogna, C., Calattini, S., Galazzi, M., Meroni, L., Manganaro, D., Fasan, M., Moroni, M., Galli, M., Parravicini, C. Blood (2001) [Pubmed]
  29. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Ljungman, P., Deliliers, G.L., Platzbecker, U., Matthes-Martin, S., Bacigalupo, A., Einsele, H., Ullmann, J., Musso, M., Trenschel, R., Ribaud, P., Bornhäuser, M., Cesaro, S., Crooks, B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A.J., Wacker, P., Cordonnier, C. Blood (2001) [Pubmed]
  30. Cidofovir added to highly active antiretroviral therapy in AIDS-associated progressive multifocal leukoencephalopathy. Herrero-Romero, M., Cordero, E., López-Cortés, L.F., de Alarcón, A., Pachón, J. AIDS (2001) [Pubmed]
  31. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Marra, C.M., Rajicic, N., Barker, D.E., Cohen, B.A., Clifford, D., Donovan Post, M.J., Ruiz, A., Bowen, B.C., Huang, M.L., Queen-Baker, J., Andersen, J., Kelly, S., Shriver, S. AIDS (2002) [Pubmed]
WikiGenes - Universities